Show simple item record

dc.contributor.authorOttaviano, M
dc.contributor.authorCurvietto, M
dc.contributor.authorRescigno, P
dc.contributor.authorTortora, M
dc.contributor.authorPalmieri, G
dc.contributor.authorGiannarelli, D
dc.contributor.authorAieta, M
dc.contributor.authorAssalone, P
dc.contributor.authorAttademo, L
dc.contributor.authorAvallone, A
dc.contributor.authorBloise, F
dc.contributor.authorBosso, D
dc.contributor.authorBorzillo, V
dc.contributor.authorBuono, G
dc.contributor.authorCalderoni, G
dc.contributor.authorCaputo, F
dc.contributor.authorCartenì, G
dc.contributor.authorCavallero, D
dc.contributor.authorCavo, A
dc.contributor.authorCiardiello, F
dc.contributor.authorConca, R
dc.contributor.authorConteduca, V
dc.contributor.authorDe Falco, S
dc.contributor.authorDe Felice, M
dc.contributor.authorDe Laurentiis, M
dc.contributor.authorDe Placido, P
dc.contributor.authorDe Placido, S
dc.contributor.authorDe Santo, I
dc.contributor.authorDe Stefano, A
dc.contributor.authorDella Corte, CM
dc.contributor.authorDi Franco, R
dc.contributor.authorDi Lauro, V
dc.contributor.authorFabbrocini, A
dc.contributor.authorFederico, P
dc.contributor.authorFestino, L
dc.contributor.authorGiordano, P
dc.contributor.authorGiuliano, M
dc.contributor.authorGridelli, C
dc.contributor.authorGrimaldi, AM
dc.contributor.authorLia, M
dc.contributor.authorMarretta, AL
dc.contributor.authorMassa, V
dc.contributor.authorMennitto, A
dc.contributor.authorMerler, S
dc.contributor.authorMerz, V
dc.contributor.authorMessina, C
dc.contributor.authorMessina, M
dc.contributor.authorMilano, M
dc.contributor.authorMinisini, AM
dc.contributor.authorMontesarchio, V
dc.contributor.authorMorabito, A
dc.contributor.authorMorgillo, F
dc.contributor.authorMucci, B
dc.contributor.authorNappi, L
dc.contributor.authorNapolitano, F
dc.contributor.authorPaciolla, I
dc.contributor.authorPagliuca, M
dc.contributor.authorPalmieri, G
dc.contributor.authorParola, S
dc.contributor.authorPepe, S
dc.contributor.authorPetrillo, A
dc.contributor.authorPiantedosi, F
dc.contributor.authorPiccin, L
dc.contributor.authorPicozzi, F
dc.contributor.authorPietroluongo, E
dc.contributor.authorPignata, S
dc.contributor.authorPrati, V
dc.contributor.authorRiccio, V
dc.contributor.authorRosanova, M
dc.contributor.authorRossi, A
dc.contributor.authorRusso, A
dc.contributor.authorSalati, M
dc.contributor.authorSantabarbara, G
dc.contributor.authorSbrana, A
dc.contributor.authorSimeone, E
dc.contributor.authorSilvestri, A
dc.contributor.authorSpada, M
dc.contributor.authorTarantino, P
dc.contributor.authorTaveggia, P
dc.contributor.authorTomei, F
dc.contributor.authorVincenzo, T
dc.contributor.authorTrapani, D
dc.contributor.authorTrojanello, C
dc.contributor.authorVanella, V
dc.contributor.authorVari, S
dc.contributor.authorVentriglia, J
dc.contributor.authorVitale, MG
dc.contributor.authorVitiello, F
dc.contributor.authorVivaldi, C
dc.contributor.authorvon Arx, C
dc.contributor.authorZacchi, F
dc.contributor.authorZampiva, I
dc.contributor.authorZivi, A
dc.contributor.authorDaniele, B
dc.contributor.authorAscierto, PA
dc.contributor.authorSCITO (Società Campana di ImmunoTerapia Oncologica)
dc.date.accessioned2021-02-15T11:19:25Z
dc.date.available2021-02-15T11:19:25Z
dc.identifier.citationJournal for immunotherapy of cancer, 2020, 8 (2)
dc.identifier.issn2051-1426
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4346
dc.identifier.eissn2051-1426
dc.identifier.doi10.1136/jitc-2020-001154
dc.description.abstractBackground The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region.Methods This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ 2 test for trends relative to the questions with 3 or more options.Results This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones.Conclusion Our study highlights the efforts of Italian oncologists to maintain high standards of care for CPs treated with ICIs, regardless the regional prevalence of COVID-19, suggesting the adoption of similar solutions. Research on patients treated with ICIs and experiencing COVID-19 will clarify the safety profile to continue the treatments, thus informing on the most appropriate clinical conducts.
dc.formatPrint
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.subjectSCITO (Società Campana di ImmunoTerapia Oncologica)
dc.subjectHumans
dc.subjectPneumonia, Viral
dc.subjectCoronavirus Infections
dc.subjectNeoplasms
dc.subjectPrevalence
dc.subjectMedical Oncology
dc.subjectInfection Control
dc.subjectGeography
dc.subjectAdult
dc.subjectItaly
dc.subjectFemale
dc.subjectMale
dc.subjectDrug Prescriptions
dc.subjectPandemics
dc.subjectCTLA-4 Antigen
dc.subjectProgrammed Cell Death 1 Receptor
dc.subjectTime-to-Treatment
dc.subjectSurveys and Questionnaires
dc.subjectPractice Patterns, Physicians'
dc.subjectOncologists
dc.subjectBetacoronavirus
dc.subjectAntineoplastic Agents, Immunological
dc.subjectB7-H1 Antigen
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.titleImpact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
dc.typeJournal Article
dcterms.dateAccepted2020-08-08
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1136/jitc-2020-001154
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal for immunotherapy of cancer
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.volume8
pubs.embargo.termsNot known
icr.researchteamProstate Cancer Targeted Therapy Group
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorRescigno, Pasqualeen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0